This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharmion's Loss Widens, but Sales Rise

Pharmion (PHRM) reported a third-quarter loss Wednesday, but revenue beat expectations and the company raised full-year guidance.

The company reported a net loss of $21.4 million, or 58 cents a share, compared with a loss of $3.6 million, or 11 cents a share in the year-ago quarter.

Pharmion's quarter included a charge of $8 million for a milestone payment triggered by the acceptance of its marketing application for cancer drug Satraplatin by the European Medicines Agency.

Net sales were $67.3 million, compared with $61.6 million in the year-ago quarter. Analysts surveyed by Thomson Financial estimated a loss of 43 cents a share on revenue of $66.4 million.

Pharmion raised its 2007 revenue guidance to $265 million to $270 million, from a prior range of $250 million to $260 million.

Worldwide sales of Vidaza, an injection for myelodysplastic syndromes (MDS), totaled $42.3 million in the third quarter of 2007, compared with $36.6 million in the same quarter of 2006. The company said it's on track to file for accelerated approval for Vidaza in Europe by year-end.

Shares closed Wednesday up 83 cents, or 1.8%, at $48.12, but were down $1.12, or 2.3%, to $47 in after-hours trading.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $124.25 0.00%
FB $81.66 0.00%
GOOG $542.56 0.00%
TSLA $187.59 0.00%
YHOO $44.13 0.00%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs